Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Agennix

Status and phase

Completed

Phase 2

Conditions

Non-small Cell Lung Cancer

Treatments

Drug: Satraplatin in combination with Paclitaxel

Study type

Interventional

Funder types

Industry

Identifiers

NCT00268970

SAT2-05-05

Details and patient eligibility

About

The purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).

Full description

This trial is designed to study the efficacy and safety of a novel oral platinum analog, satraplatin, in combination with another chemotherapy drug, paclitaxel, for the first line of treatment (patients who have not received chemotherapy for disease that has metastasized) of patients with advanced NSCLC.

WHAT IS SATRAPLATIN:

Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

Enrollment

40 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Histologically confirmed advanced NSCLC
Patients must not have received any prior antineoplastic chemotherapy or investigational product for lung cancer prior to study entry.
Patients must have at least one unidimensionally measurable lesion definable by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
ECOG performance status of ≤ 2.